原发性甲状腺淋巴瘤的生存结局与治疗策略:东京癌症登记处401例人群研究
该回顾性人群研究基于东京癌症登记处2012-2020年登记的401例原发性甲状腺淋巴瘤患者,中位随访3.3年,发现疾病特异性死亡集中在诊断后前两年尤其是前六个月,高龄(≥80岁)和弥漫大B细胞淋巴瘤(DLBCL)与较差的总生存(OS)和疾病特异性生存(DSS)相关,当前淋巴瘤分期系统未显著区分生存,IE期患者单纯局部治疗(包括治愈性手术)观察到良好结局。
要点
- 疾病特异性死亡集中在诊断后前两年,尤其前六个月,是关键管理期。
- 高龄(≥80岁)和DLBCL组织学亚型与较差的OS和DSS独立相关。
- IE期患者接受单纯局部治疗(包括治愈性手术)观察到良好结局。
核心结论
- 原发性甲状腺淋巴瘤疾病特异性死亡最高在诊断后前两年,尤其前六个月,强调及时治疗的重要性。
- 高龄和DLBCL组织学亚型仍是OS和DSS的关键决定因素,老年和DLBCL患者结局较差。
- 部分IE期患者单纯手术治疗观察到良好结局,提示对特定患者可考虑较低强度治疗。
研究设计与样本
- 回顾性人群基础研究,分析东京癌症登记处(TCR)2012-2020年登记的401例原发性甲状腺淋巴瘤病例。
主要发现
- 中位随访3.3年(四分位距1.2-5.5年)。
- 疾病特异性死亡集中在诊断后前两年,尤其前六个月。
- 高龄(≥80岁)和DLBCL与较差OS和DSS相关。
- 当前淋巴瘤分期系统未显著区分生存结局。
- IE期患者接受单纯治愈性手术等局部治疗观察到良好结局。
临床怎么用
- 对原发性甲状腺淋巴瘤患者,诊断后前两年尤其是前六个月应加强监测和及时治疗。
- 高龄和DLBCL患者需更积极管理以改善生存。
- 对选择性的IE期患者,单纯手术等局部治疗可能适当,避免过度治疗。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- 中位随访时间较短(3.3年),可能不足以评估长期结局。
- 缺乏标准化治疗指南,治疗策略异质性可能影响结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: There is limited information about the clinical behavior and no standardized treatment guidelines for primary thyroid lymphoma (PTL). Prognostic factors and treatment outcomes remain poorly defined despite diagnostic and therapeutic advancements. We evaluated PTL survival outcomes and treatment strategies, using a large population-based cohort from the Tokyo Cancer Registry (TCR), a government-operated database that systematically collects cancer incidence and outcome data in Tokyo, Japan. Patients and Methods: This retrospective, population-based study analyzed PTL cases registered in 2012-2020 in the TCR. The patients (n = 401) were identified through an International Classification of Diseases for Oncology, third edition topography code C73.9 (thyroid gland) and nonthyroidal lymphoma ICD-10 codes. Results: The median follow-up was 3.3 years (interquartile range, 1.2-5.5 years). Disease-specific mortality was concentrated in the first two years postdiagnosis, particularly in the initial six months. Advanced age (≥80 years) and diffuse large B-cell lymphoma (DLBCL) were associated with poorer overall survival (OS) and disease-specific survival (DSS). The current lymphoma staging systems do not significantly differentiate survival outcomes. Favorable outcomes were observed with localized treatments, including curative surgery alone, for stage IE PTL. Conclusions: Disease-specific mortality was highest in the first two years, particularly the first six months, highlighting this as a critical management period and the importance of timely treatment. Despite recent treatment advances that have improved the overall prognosis and reduced prognostic differences among disease stages, age at diagnosis and histological subtype remain key OS and DSS determinants, with older patients and DLBCL patients experiencing poorer outcomes. Notably, favorable outcomes were observed in selected Stage IE cases treated with surgery alone, suggesting that less-intensive treatment may be appropriate for certain PTL patients.
引用
- Saito Y, Watanabe N, Inoue K, et al. Survival Outcomes and Treatment Strategies in Primary Thyroid Lymphoma: A Population-Based Study of 401 Cases from the Tokyo Cancer Registry. Thyroid. 2025. PMID: 41196039. doi:10.1177/10507256251393514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。